Profile
Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.
We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.
BROAD STRATEGIC APPROACH
Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.
Vast experience: check. Deep expertise: check. Easy accessibility: check. After decades of investing from offices in the most important centers of biotechnology worldwide, Abingworth offers entrepreneurs an unmatched combination of all three of these key attributes.
We can help attract talent for boards and leadership teams, choose drug targets for novel platforms, devise plans for clinical development, navigate legal issues, advise on PR strategy and think through corporate development and exit strategies. Adding to our own knowledge, we have a wide network of leading scientific and industry experts. Our collective experience is offered to all portfolio companies.
Industry
Region of investment
Abingworth Funds
Name | Type |
|
|
|
Size | AUM | Launch date |
---|---|---|---|---|---|---|---|
Abingworth Clinical Co-Development Fund
|
Venture Capital (VC)
|
Biotechnology
Technology
Life Sciences
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$105 M
|
January 2016
|
Fund VII
|
Venture Capital (VC)
|
Healthcare Services
Technology
Life Sciences
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$220 M
|
August 2017
|
Abingworth Bioventures VII
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Pharmaceuticals
Life Sciences
|
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$315 M
|
July 2018
|
Abingworth Bioventures VIII
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Pharmaceuticals
Technology
Life Sciences
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$465 M
|
February 2021
|
Abingworth Clinical Co-Development Co-Investment Fund
|
Venture Capital (VC)
|
Biotechnology
Fintech
Healthcare Services
Life Sciences
|
Pre-seed
Seed
Series A
|
North America
Europe
|
$5-10 m
|
$356 M
|
October 2023
|